HDAC9 and urinary bladder cancer: Since the relevance of HDAC suppression for drug-resistant bladder cancer cells has not yet been evaluated, we explored whether the HDAC inhibitor valproic acid (VPA) exerts anti-tumor properties on a panel of temsirolimus-resistant bladder cancer cell lines.